Inhibikase Therapeutics (IKT) Competitor Comparison
We are evaluating the key criteria listed to compare Inhibikase Therapeutics (IKT) against its competitors in the Biotechnology industry.
Market Capitalization
338 / 368Gross Profits
0 / 278Total Revenue
261 / 300EBITDA
83 / 337Free Cashflow
103 / 352Quick Ratio
150 / 357Earnings per Share
268 / 359Dividend yield
0 / 6Total Cash
305 / 358Performance 3 years
251 / 368Performance 5 years
338 / 368Performance 10 years
306 / 368Linearity 3 years
246 / 368Linearity 5 years
317 / 368Linearity 10 years
304 / 368Total Rank
156 / 368Dividend Rank
161 / 368Valuation Rank
350 / 368Piotroski Rank
131 / 368Muliplier Rank
80 / 368Total Cash - IKT ranking 305 / 358
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.